On June 9, 2026, Luke Evnin, serving as a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), completed the sale of 76,928 shares of the company's common stock. The aggregate value of this transaction was recorded at $28,463. The execution of the sale involved a price range of $0.3553 to $0.3851 per share. This activity takes place against a backdrop where the stock is trading close to its 52-week low of $0.35, with the share price having declined by 11% over the preceding week to reach $0.37.
The disposition of these shares was facilitated through a Rule 10b5-1 trading plan, which was initially established on March 26, 2026. The shares were not sold directly by Mr. Evnin but were disposed of indirectly through a network of affiliated entities. The breakdown of the sale by entity includes 8,242 shares transferred by MPM Asset Management LLC, 52,039 shares by MPM BioVentures 2014, L.P., 3,471 shares by MPM BioVentures 2014(B), L.P., 1,791 shares by MPM Asset Management Investors BV2014 LLC, and 11,385 shares by MPM Oncology Innovations Fund, L.P.
Mr. Evnin holds specific roles within these entities, serving as a member of MPM Asset Management LLC, a Managing Director of MPM BioVentures 2014 LLC which acts as the general partner for several of the involved entities, and a manager of MPM Oncology Innovations Fund GP LLC. Despite his managerial and directorial roles, Mr. Evnin has disclaimed beneficial ownership of the securities, with the exception of his pecuniary interest.
Following the completion of these transactions, Mr. Evnin's indirect holding of Werewolf Therapeutics common stock through the various entities stands at 300,283 shares. According to InvestingPro analysis, the stock appears undervalued at current levels, with additional insights available on the platform's most undervalued stocks list. The transaction highlights the ongoing activity within the biotech sector, where director-level trades are closely monitored for signals regarding internal confidence and valuation perceptions.